Diffusion Pharmaceuticals receives new U.S. patents for trans sodium crocetinate

Diffusion Pharmaceuticals LLC, a biotechnology company focused on innovative cancer treatments, today announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled "Bipolar Trans Carotenoids Salts and Their Uses" and "Trans Carotenoids, Their Synthesis and Uses," respectively. These patents include compound, composition, and methods of use relating to Diffusion's lead molecule, trans sodium crocetinate (TSC), as well as the entire family of first-in-class new chemical entities in the Company's pipeline of therapeutic candidates. Diffusion Pharmaceuticals is commercializing this family of first-in-class drugs to treat serious or life-threatening medical conditions characterized by hypoxia or oxygen deprivation at the cellular level. Enrollment is currently underway in a multi-center Phase I/II study of TSC for the improved treatment of newly diagnosed primary brain cancer patients.    

"These new patents are important additions to our intellectual property portfolio, providing strong protection through at least 2027," said David G. Kalergis, Diffusion's CEO.

Currently the Company has 7 issued U.S. patents, 10 issued foreign patents and more than 70 pending patent applications filed in all major international markets.

Source: Diffusion Pharmaceuticals